Retinal angiomatous proliferation.
Retinal angiomatous proliferation (RAP) is a distinct form of choroidal neovascularization which may complicate a wet age related macular degeneration (AMD). This exudative-AMD has a peculiar clinical history and prognosis. RAP accounts from 8% to 22% of newly diagnosed cases among patients previously diagnosed as exudative AMD, and up to 25% of the occult or minimally classic CNV. The disease is more prevalent in women (90% of cases) and in elderly patients (around 75 years), and is characterized by a very poor prognosis. The neovascular process, whose retinal or choroidal origin is still object of discussion, often hesitates in the formation of a disciform scar, that evolves into a severe loss of central vision. Treatment for RAP is not yet well established; herein are described the most used therapeutic strategies, starting from laser photocoagulation until the nearest anti VEGF. The opportunity of combination among various treatments to obtain a better effectiveness and a lower frequency of recurrence is also discussed.
Marticorena
J
J
Instituto Tecnológico de Oftalmologia, Santiago de Compostela, Spain. jmarticorena@gmail.com
Di Leva
V
V
Cennamo
G L
GL
de Crecchio
G
G
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001766:Blindness / Q000209:etiology / Q000517:prevention & control*; D003131:Combined Modality Therapy; D006801:Humans; D017075:Laser Coagulation; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use; D011379:Prognosis; D015861:Retinal Neovascularization / Q000188:drug therapy / Q000209:etiology / Q000601:surgery / Q000628:therapy*; D042442:Vascular Endothelial Growth Factors / Q000037:antagonists & inhibitors; D057135:Wet Macular Degeneration / Q000175:diagnosis / Q000503:physiopathology*
D020533:Angiogenesis Inhibitors; D000893:Anti-Inflammatory Agents; D017319:Photosensitizing Agents; D042442:Vascular Endothelial Growth Factors